



## Torrent Pharmaceuticals Limited – Recall of anagrelide

- On December 9, 2020, [Torrent Pharmaceuticals Limited announced](#) a voluntary recall of one lot of [anagrelide](#) 1 mg capsules due to dissolution test failure detected during routine quality testing.
  - Torrent Pharmaceuticals is only recalling some bottles of anagrelide capsules. Other anagrelide capsules are available for patients to use and are not being recalled.
- Clinical Services, through the Drug Safety Notification program, will conduct a mailing to members and providers that may be affected by the recall.
  - The letters provide instructions on how members can identify if their medication is being recalled, what to do if they have the recalled product, and information regarding potential risks associated with using the recalled product.
- If patients have the recalled anagrelide, they should continue taking it and contact their pharmacy for a safe replacement. There are other bottles of anagrelide capsules that are not being recalled and a new prescription may not be needed.
- The recalled lot is listed below.

Product Description	NDC#	Lot# (Expiration Date)
Anagrelide 1 mg capsules	13668-462-01	BFD1G001 (12/2021)

- Anagrelide is a platelet-reducing agent indicated for the treatment of patients with thrombocytopenia, to reduce the risk of thrombosis and associated symptoms including thrombo-hemorrhagic events.
- Failed dissolution can result in a slower rate and extent of drug release leading to less anagrelide available in the body. For seriously ill patients with elevated platelet counts, less available anagrelide could increase the risk of clotting and clotting or bleeding events such as a heart attack or stroke which could be life-threatening.
- To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled anagrelide.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.

- Contact Torrent Pharmaceuticals Limited by phone at **800-912-9561** or by email at [medinfo.Torrent@apcerls.com](mailto:medinfo.Torrent@apcerls.com) for more information.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.